Skip to content
medsupport
Healthcare investing, in context.
Search pages:
Search
Menu
☰
Biotech
Market Economics
Assessing Competition: Standards of Care, Competing Pipelines and Treatment Differentiation
Biotech Manufacturing: Scale-Up, Quality Control, Capacity and Production Costs
Biotech Patents and Regulatory Exclusivity: What Protects Commercial Value
Patent Expiry, Generic Competition and Biosimilars
Drug Launches and Adoption: Physician Decisions, Patient Access and Sales Execution
Drug Pricing, Reimbursement and Market Access Explained
Estimating a Drug’s Addressable Market: From Disease Prevalence to Eligible Patients
Financial Analysis and Valuation
Cash Burn and Cash Runway: Funding Development Through the Next Milestone
Debt, Convertible Securities and Royalty Financing in Biotech
Market Capitalisation, Enterprise Value and Biotech Stocks Trading Below Cash
Risk-Adjusted Net Present Value for Biotech Pipelines
Estimating Clinical and Regulatory Success Probabilities
Testing Valuation Assumptions: Peak Sales, Launch Timing, Costs and Discount Rates
Share Dilution, Equity Offerings and Financing Risk in Biotech
Valuing Biotech Licensing Deals: Upfront Payments, Milestones and Royalties
Investing
Biotech Catalysts: Trial Results, Regulatory Decisions and Partnerships
Biotech Investing Glossary: Scientific, Regulatory and Financial Terms
Biotech Platforms vs Single-Asset Businesses
Early-Stage, Clinical-Stage and Commercial-Stage Biotech Investing
Healthcare, Agricultural and Industrial Biotech: Different Investment Drivers
Researching Biotech Through Scientific Papers, Trial Registries and Financial Filings
Copy Trading
Portfolio Construction and Risk
Biotech Market Cycles: Interest Rates, Funding Conditions and Investor Sentiment
Direct Biotech Investing vs ETFs and Specialist Funds
Diversification Across Drug Technologies, Disease Areas and Development Stages
Position Sizing Around Clinical Readouts and Regulatory Decisions
Science and Drug Technologies
AI in Drug Discovery: Assessing Evidence Behind Claims of Faster Development
Antibody Therapies and Antibody–Drug Conjugates Explained for Investors
Cell Therapies: Scientific Potential, Manufacturing Challenges and Commercial Constraints
Drug Targets and Mechanisms of Action: Evaluating the Scientific Rationale
Gene Therapies: Delivery, Durability and Investment Considerations
Gene Editing: Evaluating Precision, Delivery and Long-Term Uncertainty
RNA Therapeutics: How They Work and What Determines Their Commercial Potential
Small-Molecule Drugs vs Biologics: Development and Investment Differences
Clinical Trials and Regulation
Clinical Trial Design: Randomisation, Blinding, Control Groups and Patient Selection
Clinical Endpoints: Measuring Whether a Treatment Works
Clinical Trial Statistics: Effect Sizes, Confidence Intervals, Power and P-Values
Reading Safety Data: Adverse Events, Treatment Discontinuations and Benefit–Risk Balance
FDA and EMA Drug Approval Processes Explained for Investors
Accelerated and Conditional Approvals: Evidence Requirements and Remaining Obligations
Regulatory Setbacks: Clinical Holds, Rejected Applications and Additional Studies
How to Read Clinical Trial Results and Assess Their Investment Significance
Selective Reporting, Subgroup Claims and Missing Data in Trial Announcements
Phase 1, Phase 2 and Phase 3 Trials Explained for Investors
Preclinical Research: What Laboratory and Animal Studies Can Establish
Links
Contact Us
iron rich food
